Morningstar has valued the stock at $207 (up from $200 immediately prior to release of full year results).
They attribute approximately $57 of this $207 to the success of CSL112 (i.e. if it failed, they would removed $57 from share price valuation). They have a 50% chance of success on the CSL112 drug so I imagine if it became successful, Morningstar would add $57 to valuation.
A while ago someone posted that Goldman Sachs have a price target of $225. Does anyone have updated reports or price targets from Goldman Sachs or other brokers?
Broker targets
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$275.80 |
Change
0.410(0.15%) |
Mkt cap ! $133.2B | |||
| Open | High | Low | Value | Volume |
| $276.00 | $277.50 | $274.44 | $131.0M | 472.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83 | $275.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $275.93 | 109 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$276.25 |
Change
0.410 ( 0.14 %) |
||||
| Open | High | Low | Volume | ||
| $276.01 | $277.50 | $274.48 | 149758 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| CSL (ASX) Chart |